MDS-249: OutcomesWith Imetelstat by Serum Erythropoietin (sEPO) Levels in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) Who Were Treatment Naive or Who Had Prior Treatment With Erythropoiesis-Stimulating Agents (ESAs)
Year: 2025
Type: conference-abstract
Authors: Rami S. Komrokji, Michael R. Savona, Valeria Santini, Amer M. Zeidan, Mikkael A. Sekeres, Pierre Fenaux, Azra Raza, Moshe Mittelman, Sylvain Thépot, Rena Buckstein, Ulrich Germing, María Díez-Campelo, David Valcárcel, Anna Jonášová, Qi Xia, Libo Sun, Shyamala Navada, Tymara Berry, Faye Feller, Uwe Platzbecker, Yazan F. Madanat
Institutions: Moffitt Cancer Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Yale Cancer Center, Yale University, University of Miami, Sylvester Comprehensive Cancer Center, Université Paris Cité, Hôpital Saint-Louis, Columbia University Irving Medical Center, Tel Aviv University, Tel Aviv Sourasky Medical Center, Centre Hospitalier Universitaire d'Angers, Sunnybrook Health Science Centre, Sunnybrook Hospital, Odette Cancer Centre, Düsseldorf University Hospital, Heinrich Heine University Düsseldorf, Vall d'Hebron Hospital Universitari, Geron (United States), University Hospital Carl Gustav Carus, Nationales Centrum für Tumorerkrankungen Dresden, Technische Universität Dresden, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4413782896